Evidence map›Paper›PMID 36208123›Full record

ArticleESC heart failure2023

Characteristics and management of very elderly patients with heart failure: a retrospective, population cohort study.

Mona Olofsson, Krister Lindmark, Jan Stålhammar, Michael Törnblom, Anna Lundberg, Gerhard Wikström, Kurt Boman

Open access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Mona OlofssonResearch Unit, Medicine-Geriatric, Skellefteå County Hospital, Skellefteå, Sweden.
Krister LindmarkDepartment of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Jan StålhammarDepartment of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden.
Michael TörnblomIQVIA, Solna, Sweden.
Anna LundbergNovartis Sweden AB, Stockholm, Sweden.
Gerhard WikströmDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Kurt BomanResearch Unit, Medicine-Geriatric, Skellefteå County Hospital, Skellefteå, Sweden.
Umeå University · SEUppsala University · SEIQVIA (United States) · USNovartis (Sweden) · SESkellefteå Hospital · SE

Funding

Novartis Pharma AG
6 · The paper itself

Abstract

aimsUnmet needs exist in the diagnosis and treatment of heart failure (HF) in the elderly population. Our aim was to analyse and compare data of diagnostics and management of very elderly patients (aged ≥85 years) compared with younger patients (aged 18-84 years) with HF in Sweden.

methodsIncidence of ≥2 HF diagnosis (ICD-10) was identified from primary/secondary care in Uppsala and Västerbotten during 2010-2015 via electronic medical records linked to data from national health registers. Analyses investigated the diagnosis, treatment patterns, hospitalizations and outpatient visits, and mortality.

resultsOf 8702 patients, 27.7% were ≥85 years old, women (60.2%); most patients (80.7%) had unknown left ventricular ejection fraction; key co-morbidities comprised anaemia, dementia, and cerebrovascular disease. More very elderly patients received cardiovascular disease (CVD)-related management after diagnosis in primary care (13.6% vs. 6.5%; P < 0.0001), but fewer patients underwent echocardiography (19.3% vs. 42.9%; P < 0.0001). Within 1 year of diagnosis, very elderly patients were less likely to be hospitalized (all-cause admissions per patient: 1.9 vs. 2.3; P < 0.0001; CVD-related admissions per patient: 1.8 vs. 2.1; P = 0.0004) or prescribed an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) plus a β-blocker (45.2% vs. 56.9%; P < 0.0001) or an ACEI/ARB plus a β-blocker plus a mineralocorticoid receptor antagonist (15.4% vs. 31.7%; P < 0.0001). One-year mortality was high in patients ≥85 years old, 30.5% (CI: 28.3-32.7%) out of 1797 patients.

conclusionsDespite the large number of very elderly patients with newly diagnosed HF in Sweden, poor diagnostic work-up and subsequent treatment highlight the inequality of care in this vulnerable population.

Indexed as

Angiotensin-Converting Enzyme InhibitorsHeart FailureAdolescentAdultAgedAged, 80 and overAngiotensin Receptor AntagonistsCohort StudiesFemaleHumansMaleMiddle AgedRetrospective StudiesStroke VolumeVentricular Function, LeftYoung AdultAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsElderlyHeart failureHospitalizationMortalitySwedenTreatment

Identifiers

PMID36208123
PMCPMC9871701
OpenAlexW4303644781

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.